What are the current GINA (Global Initiative for Asthma) guidelines for initiating and stepping up asthma controller therapy?

GINA Guidelines for Asthma Controller Therapy

For all adults and adolescents with asthma, initiate inhaled corticosteroid (ICS)-containing therapy immediately—never treat with short-acting beta-agonist (SABA) alone, as this significantly increases the risk of severe exacerbations and death. 1, 2, 3

Two Treatment Tracks (GINA 2024)

The current GINA strategy divides asthma management into two distinct tracks:

Track 1 (Preferred Approach)

• Reliever medication: As-needed low-dose ICS-formoterol at ALL steps
• Steps 1-2 (Mild asthma): ICS-formoterol as needed only
• Steps 3-5 (Moderate-severe): Daily maintenance ICS-formoterol PLUS as-needed ICS-formoterol (MART - Maintenance and Reliever Therapy)
• Evidence: Reduces severe exacerbations by ≥60% compared to SABA alone in mild asthma 2

Track 2 (Alternative)

• Reliever medication: As-needed SABA across all steps
• Step 2: Regular low-dose ICS
• Steps 3-5: ICS-LABA combination therapy
• Use this track only when Track 1 medications are unavailable or unaffordable 1, 2

Stepwise Treatment Algorithm

Step 1 (Intermittent symptoms)

• Track 1: As-needed low-dose ICS-formoterol only
• Track 2: As-needed SABA (NOT recommended as sole therapy)

Step 2 (Mild persistent)

• Track 1: As-needed low-dose ICS-formoterol
• Track 2: Daily low-dose ICS + as-needed SABA

Step 3 (Moderate)

• Track 1: Low-dose maintenance ICS-formoterol + as-needed ICS-formoterol (MART)
• Track 2: Low-dose ICS-LABA + as-needed SABA

Step 4 (Moderate-severe)

• Track 1: Medium-dose maintenance ICS-formoterol + as-needed ICS-formoterol (MART)
• Track 2: Medium-dose ICS-LABA + as-needed SABA

Step 5 (Severe)

• High-dose ICS-LABA (MART or fixed-dose)
• Add-on options: Long-acting muscarinic antagonist (LAMA), azithromycin, or biologic therapy
• Consider oral corticosteroids only if other options exhausted 2

When to Step Up or Down

Step up if:

• Asthma remains uncontrolled after 4-6 weeks
• Inhaler technique and adherence verified
• Environmental triggers addressed
• Comorbidities managed

Step down if:

• Asthma well-controlled for ≥3 consecutive months
• Reduce by one step at a time
• Monitor closely for 3 months after reduction 4

Critical Pitfalls to Avoid

1. Never prescribe SABA monotherapy: This is the single most dangerous practice—increases mortality risk
2. Don't wait to start ICS: Even "mild" asthma requires ICS-containing therapy
3. Verify inhaler technique before stepping up: Poor technique mimics uncontrolled asthma
4. Check adherence objectively: Most "difficult asthma" is actually non-adherence
5. Assess for treatable traits: Rhinitis, GERD, obesity, smoking, allergen exposure all worsen control 5

Age-Specific Modifications

Children 6-11 years 4:

• Step 1: PRN SABA (though ICS-containing preferred)
• Step 2: Daily low-dose ICS + PRN SABA
• Step 3: Medium-dose ICS OR low-dose ICS-LABA
• Step 4: Medium-dose ICS-LABA
• Consult specialist at Step 3 or higher

Children 0-4 years 4:

• Step 1: PRN SABA
• Step 2: Daily low-dose ICS
• Step 3: Medium-dose ICS
• Step 4: Medium-dose ICS-LABA (age 4 only)
• Consider specialist consultation at Step 2

Essential Non-Pharmacologic Management

Every patient requires:

• Written asthma action plan (mandatory, not optional)
• Inhaler technique assessment at every visit
• Environmental control: Multi-component allergen mitigation for sensitized patients (dust mites, pets, pests) 4
• Smoking cessation: Active and passive exposure
• Comorbidity management: Rhinitis, GERD, obesity, anxiety

Monitoring and Assessment

Assess at every visit:

• Symptom control: Daytime symptoms, night waking, activity limitation, reliever use
• Future risk: Exacerbation history, lung function decline, medication side effects
• Objective measures: Spirometry (FEV1), peak flow monitoring
• FENO testing: Consider for phenotyping and monitoring type-2 inflammation 4

Red flags requiring immediate step-up or specialist referral:

• ≥2 SABA uses per week (excluding pre-exercise)
• Any night waking due to asthma
• Any activity limitation
• History of ICU admission or intubation
• ≥1 severe exacerbation in past year

The fundamental paradigm shift in modern asthma management is that all asthma requires anti-inflammatory therapy with ICS, and the combination of ICS-formoterol as both maintenance and reliever represents the most effective strategy for preventing exacerbations across the severity spectrum 1, 2, 3.